TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7575309

Group type: EXPERIMENTAL
Intervention: Stopping motion challenges at initial symptoms
Number of subjects: 20

Group type: COMPARATOR
Intervention: Stopping motion challenges at moderate nausea
Number of subjects: 20
Study: 2328174

Group type: EXPERIMENTAL
Intervention: i.v. diamorphine using a patient‐controlled analgesia system (PCAS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: extradural diamorphine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: i.m. morphine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 7261664

Group type: EXPERIMENTAL
Intervention: clobetasone butyrate 0.05%
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: fluocortin butylester 0.75%
Number of subjects: 29

Group type: COMPARATOR
Intervention: hydrocortisone acetate 1%
Number of subjects: 29

Group type: COMPARATOR
Intervention: placebo creams
Number of subjects: 29
Study: 30506558

Group type: EXPERIMENTAL
Intervention: Carbetocin 20 μg
Number of subjects: 108

Group type: COMPARATOR
Intervention: Carbetocin 100 μg
Number of subjects: 108
Study: 28526920

Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg once-weekly
Number of subjects: 75

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study: 25940767

Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy (MST)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Telephone support condition (Control)
Number of subjects: 146
Study: 23374910

Group type: EXPERIMENTAL
Intervention: Hotspot-targeted interventions including larviciding, focal screening and treatment, distribution of long-lasting insecticide-treated nets, and indoor residual spraying.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study: 21272393

Group type: EXPERIMENTAL
Intervention: cCBT (Think, Feel, Do)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control condition (delayed cCBT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Feedback from participants
Number of subjects: 20
Study: 19320633

Group type: EXPERIMENTAL
Intervention: Baseline measures of perceived stress, drinking severity, psychiatric comorbidity, self-efficacy, craving, and positive treatment outcome expectancies
Number of subjects: 0
Study: 17353403

Group type: EXPERIMENTAL
Intervention: Beta carotene (50 mg every other day)
Number of subjects: 22071

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study: 15096081

Group type: EXPERIMENTAL
Intervention: Sertraline (titrated up to 50-150 mg/day)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Paroxetine (titrated up to 40-60 mg/day)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 225

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 225
Study: 12106936

Group type: EXPERIMENTAL
Intervention: Spironolactone (12.5 to 50 mg/day)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study: 9641366

Group type: EXPERIMENTAL
Intervention: Thyroxine 0.1 mg daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 7943696

Group type: EXPERIMENTAL
Intervention: Tubocurare (0.125 mg.kg‐1 or 0.25 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Suxamethonium (1 mg.kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tubocurare controls
Number of subjects: 0
Study: 3287770

Group type: EXPERIMENTAL
Intervention: Combination therapy of pirenzepine (75 mg/day) and cimetidine (400 mg at bedtime)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cimetidine monotherapy (1000 mg/day)
Number of subjects: 60
Study: 31888764

Group type: EXPERIMENTAL
Intervention: Cerebral NIRS monitoring during the first 72 hours of life
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Treatment as usual (no cerebral oxygenation monitoring)
Number of subjects: 1600
Study: 28886351

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 or 30 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no glucocorticoid treatment)
Number of subjects: 64
Study: 24699430

Group type: EXPERIMENTAL
Intervention: Computer-based working memory training and exercises in word fluency and semantic structuring
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard memory therapy provided in the rehabilitation center
Number of subjects: 36
Study: 24113708

Group type: EXPERIMENTAL
Intervention: High-repetition, moderate-intensity resistance training (n = 12) for 12 weeks, performed twice a week for 75 minutes per session.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (n = 7), no intervention.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Comparison between exercise and control groups.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both groups (exercise and control).
Number of subjects: 19
Study: 22071714

Group type: EXPERIMENTAL
Intervention: COPD patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Desaturating COPD patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: COPD patients with high CRP
Number of subjects: 28
Study: 19808135

Group type: EXPERIMENTAL
Intervention: Modafinil 300 mg/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 16980242

Group type: EXPERIMENTAL
Intervention: MAS065D (Xclair)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 20
Study: 16807617

Group type: EXPERIMENTAL
Intervention: Eprosartan mesylate 600 mg once daily
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Eprosartan mesylate 600 mg once daily plus HBPM
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group (eprosartan alone)
Number of subjects: 198
Study: 10690446

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (20 minutes of treadmill running at 70-80% of maximal heart rate)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anaerobic exercise (Wingate anaerobic test)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (untrained women)
Number of subjects: 15
Study: 9327314

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 122

Group type: COMPARATOR
Intervention: Ketanserin
Number of subjects: 122
Study: 8418225

Group type: EXPERIMENTAL
Intervention: Octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days
Number of subjects: 41
Study: 3671896

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30516088

Group type: EXPERIMENTAL
Intervention: Incentive group ($20 for top third scores)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (standard administration instructions)
Number of subjects: 81
Study: 28854956

Group type: EXPERIMENTAL
Intervention: Ultra-low dose RTX (1×500 mg or 1×200 mg)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard low dose RTX (1×1000 mg)
Number of subjects: 140
Study: 24299470

Group type: EXPERIMENTAL
Intervention: Coiling
Number of subjects: 84

Group type: COMPARATOR
Intervention: Clipping
Number of subjects: 84
Study: 24261522

Group type: EXPERIMENTAL
Intervention: School-based asthma program
Number of subjects: 1316
Study: 20931328

Group type: EXPERIMENTAL
Intervention: Pentagastrin (cholecystokinin type-2 receptor agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (pre-conditioning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone (μ-opioid receptor antagonist)
Number of subjects: 0
Study: 18814906

Group type: EXPERIMENTAL
Intervention: Short-acting human insulin (1 unit/kg)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 20929566

Group type: EXPERIMENTAL
Intervention: Malaria intervention (intermittent screening and treatment of malaria)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Literacy intervention (training workshops and support for teachers)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Both interventions combined (malaria and literacy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (neither intervention implemented)
Number of subjects: 101
Study: 16154017

Group type: EXPERIMENTAL
Intervention: Amlodipine-based combination drug regimen
Number of subjects: 19257

Group type: COMPARATOR
Intervention: Atenolol-based combination drug regimen
Number of subjects: 19257

Group type: EXPERIMENTAL
Intervention: Multivariate adjustment
Number of subjects: 19257
Study: 12039619

Group type: EXPERIMENTAL
Intervention: 1 mg buprenorphine per day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine per day
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 4 mg buprenorphine per day
Number of subjects: 105
Study: 9569110

Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy (81 mg) in Group 1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravesical BCG therapy (54 mg) in Group 2
Number of subjects: 80
Study: 8306416

Group type: COMPARATOR
Intervention: Mitomycin 20 mg/m2 only
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Mitomycin 20 mg/m2 after pretreatment with WR-2721, 910 mg/m2
Number of subjects: 97
Study: 3189495

Group type: EXPERIMENTAL
Intervention: Blu Blocker
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vuarnet 4006
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vuarnet 4006 (outdoors in shaded daylight)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 1.0 log unit neutral density filter (NDF)
Number of subjects: 22
Study: 30649344

Group type: EXPERIMENTAL
Intervention: Feeding sows once daily at 1530 h
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control (Feeding sows once daily at 0730 h)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Feeding sows daily at 1130 h
Number of subjects: 174
Study: 29432331

Group type: EXPERIMENTAL
Intervention: Fluvoxamine plus risperidone and biperiden
Number of subjects: 68

Group type: COMPARATOR
Intervention: Risperidone and biperiden (Control)
Number of subjects: 68
Study: 27545697

Group type: EXPERIMENTAL
Intervention: Colistin (2 million international units every 8 hours)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Colistin plus rifampicin (not detailed in dosage or duration)
Number of subjects: 166
Study: 24819327

Group type: EXPERIMENTAL
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: Transobturator tape (TVT-O)
Number of subjects: 569
Study: 22395280

Group type: EXPERIMENTAL
Intervention: Compressive gear (CG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No gear (NON)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study: 19145637

Group type: EXPERIMENTAL
Intervention: Daming capsule (DMC) 2 g b.i.d. for 6 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pravastatin 10 mg o.d. for 6 weeks
Number of subjects: 60
Study: 17325925

Group type: EXPERIMENTAL
Intervention: Iodixanol (320 mg Iota/ml) used in MDCTA
Number of subjects: 173
Study: 15505151

Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin (BoNT) type A injections into the submandibular salivary glands
Number of subjects: 45

Group type: COMPARATOR
Intervention: Scopolamine treatment
Number of subjects: 45
Study: 11266239

Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate (HFA-BDP) 800 microg day(-1)
Number of subjects: 198

Group type: COMPARATOR
Intervention: HFA-fluticasone propionate (HFA-FP) 1000 microg day(-1)
Number of subjects: 198
Study: 9684804

Group type: EXPERIMENTAL
Intervention: Plasminogen deficiency
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Non-deficient group
Number of subjects: 1192
Study: 7985248

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMWHs)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH), dextran, or vitamin K-antagonists
Number of subjects: 66
Study: 2968595

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) + cholestyramine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cholestyramine alone for 12 weeks
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cholestyramine (with simvastatin 20 mg/day)
Number of subjects: 24
Study: 29976233

Group type: EXPERIMENTAL
Intervention: Postpyloric enteral nutrition
Number of subjects: 141

Group type: COMPARATOR
Intervention: Gastric enteral nutrition
Number of subjects: 141
Study: 26340864

Group type: EXPERIMENTAL
Intervention: Baltimore Experience Corps program (community-based volunteer program) for 2 years
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study: 24636808

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri probiotic preparation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23576138

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus Oxaliplatin (500 mg/m² Pemetrexed + 100 mg/m² Oxaliplatin)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pemetrexed plus Cisplatin (500 mg/m² Pemetrexed + 75 mg/m² Cisplatin)
Number of subjects: 45
Study: 20005617

Group type: EXPERIMENTAL
Intervention: Community breastfeeding support groups
Number of subjects: 7
Study: 18775035

Group type: EXPERIMENTAL
Intervention: Enhanced information regarding life-sustaining treatment alternatives
Number of subjects: 78

Group type: COMPARATOR
Intervention: No information (control group)
Number of subjects: 78
Study: 16768770

Group type: EXPERIMENTAL
Intervention: Peritonectomy with heated intraperitoneal chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Complete cancer resection (CCR O)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patients with PCI score less than 13
Number of subjects: 22
Study: 11805764

Group type: EXPERIMENTAL
Intervention: Rocuronium (1.0 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vecuronium (0.15 mg/kg)
Number of subjects: 100
Study: 10563126

Group type: EXPERIMENTAL
Intervention: 6% sevoflurane in oxygen
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4.5% sevoflurane in 50% nitrous oxide
Number of subjects: 50
Study: 7786375

Group type: EXPERIMENTAL
Intervention: Ambulatory rotation (37 students)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual rotation on general medicine wards (69 students)
Number of subjects: 106
Study: 2120178

Group type: EXPERIMENTAL
Intervention: Temafloxacin 300 mg twice daily for ten days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Temafloxacin 600 mg twice daily for ten days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Temafloxacin
Number of subjects: 36
Study: 356739

Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31927581

Group type: EXPERIMENTAL
Intervention: Protein-rich diet (Prot)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Unsaturated fat-rich diet (Unsat)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich diet (Carb)
Number of subjects: 163
Study: 28982261

Group type: EXPERIMENTAL
Intervention: Central IRB review
Number of subjects: 34

Group type: COMPARATOR
Intervention: Local IRB review
Number of subjects: 34
Study: 27486817

Group type: COMPARATOR
Intervention: Sm-153-EDTMP alone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of Sm-153-EDTMP and PSA-TRICOM vaccine
Number of subjects: 44
Study: 25169910

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 88
Study: 22520644

Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg daily for 3 days prior to the abortion
Number of subjects: 16

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 16
Study: 21866687

Group type: EXPERIMENTAL
Intervention: Group A (Relactation)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group B (Control: Exclusive breastfeeding)
Number of subjects: 40
Study: 18819444

Group type: EXPERIMENTAL
Intervention: New high-cost antiepileptic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacoepidemiology studies
Number of subjects: 0
Study: 16671417

Group type: EXPERIMENTAL
Intervention: Traumatic brain injury patients with significant brain swelling
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Traumatic brain injury patients without swelling
Number of subjects: 53

Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 53
Study: 12791448

Group type: EXPERIMENTAL
Intervention: Bupivacaine hydrochloride
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (9% NaCl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine vs Dexamethasone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine vs Lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dexamethasone vs Lidocaine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexamethasone, Lidocaine vs Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bupivacaine, Dexamethasone, Lidocaine
Number of subjects: 80
Study: 10748784

Group type: EXPERIMENTAL
Intervention: Various management options for menorrhagia
Number of subjects: 0
Study: 9297773

Group type: EXPERIMENTAL
Intervention: Laser soldering technique (LTW)
Number of subjects: 37
Study: 8383270

Group type: EXPERIMENTAL
Intervention: Marijuana smoking
Number of subjects: 0
Study: 3521103

Group type: COMPARATOR
Intervention: 400 mg cimetidine b.i.d.
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine nocte
Number of subjects: 86
Study: 30260984

Group type: EXPERIMENTAL
Intervention: 20% price discount on healthy food and beverages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20% price discount on healthy food and beverages with consumer education
Number of subjects: 0
Study: 26832653

Group type: EXPERIMENTAL
Intervention: Levofloxacin Sequential Therapy (LS): lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, levofloxacin, and metronidazole for another 5 days
Number of subjects: 600

Group type: COMPARATOR
Intervention: Levofloxacin Triple Therapy (LT): lansoprazole, amoxicillin, and levofloxacin for 10 days
Number of subjects: 600
Study: 23831184

Group type: EXPERIMENTAL
Intervention: Theta-rhythm transcranial alternating current stimulation (tACS) over the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham non-active stimulation
Number of subjects: 0
Study: 21835900

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg in the cardiopulmonary bypass prime, 500 mg IV bolus following the final circulatory arrest, and 250 mg IV bolus 36 h after surgery)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 98
Study: 20627877

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion (bolus dose of 1 microg kg(‐1) followed by continuous infusion of 0.5 microg kg(‐1) h(‐1))
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion (bolus dose of 2 microg kg(‐1) followed by continuous infusion of 1 microg kg(‐1) h(‐1))
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (vehicle only)
Number of subjects: 150
Study: 19305031

Group type: EXPERIMENTAL
Intervention: Olive oil based emulsion (ClinOleic)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Soybean oil based emulsion (Ivelip)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (Olive oil and Soybean oil)
Number of subjects: 44
Study: 16164393

Group type: EXPERIMENTAL
Intervention: TNF‐α antagonists (infliximab, etanercept, adalimumab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening procedures for potential recipients of TNF‐α antagonists
Number of subjects: 0
Study: 11322864

Group type: EXPERIMENTAL
Intervention: Intravascular radiation (brachytherapy)
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Prolonged antiplatelet therapy
Number of subjects: 150000

Group type: EXPERIMENTAL
Intervention: Reduction in the number of new stents placed at the time of radiation
Number of subjects: 150000
Study: 9730394

Group type: EXPERIMENTAL
Intervention: LAP-BAND with hiatus hernia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LAP-BAND with motility disorder
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LAP-BAND with both hiatus hernia and motility disorder
Number of subjects: 50
Study: 11271240

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CyA) and Nifedipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporin (CyA)
Number of subjects: 0
Study: 2648788

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 mg twice daily for 1 week, followed by 40 mg twice daily for 3 weeks)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 19674225

Group type: EXPERIMENTAL
Intervention: 8-day university-based training course
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waiting list for training (Control)
Number of subjects: 42
Study: 367501

Group type: EXPERIMENTAL
Intervention: Hypochlorite-sterilised vessels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Holder pasteurisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated milk
Number of subjects: 0
Study: 30663824

Group type: EXPERIMENTAL
Intervention: memantine
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 29932581

Group type: EXPERIMENTAL
Intervention: Traditional mode of ventilation
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Modified ventilation mode with inversion of the respiratory cycle and high-level application of PEEP titration
Number of subjects: 37
Study: 26049551

Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 23410616

Group type: EXPERIMENTAL
Intervention: Current cannabis use (past 30 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current and recent past cannabis use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recent past cannabis use (not in past 30 days)
Number of subjects: 0
Study: 21435093

Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy (esomeprazole and amoxicillin for 7 days followed by esomeprazole, clarithromycin, and metronidazole for 7 days)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 14-day sequential therapy
Number of subjects: 123